Skip to main content

Whipple’s Rare disease New Drug Discovery and Latest Industry Growth Prospects 2019


Whipple’s disease (WD) is a rare, chronic, systemic infectious bacterial disease caused by Tropheryma whipplei that affects gastrointestinal system, especially, the small intestine. The infection may spread to any part of the body but mostly it affects the central nervous system, joints, lungs, heart, and eyes.

Ongoing research and clinical trial to find effective cure drive the growth of market. Advancement in medical technology and increasing awareness about this disease boost the market growth.


The “global Whipple’s Disease Industry is expected to grow at the CAGR of ~3.1% during the forecast period and is estimated to reach USD 255.3 million by 2023.”

Competitive Analysis:

Some of the key players in this market are –
  • AbbVie Inc. (US)
  • Allergan (Republic of Ireland)
  • Bayer AG (Germany)
  • Bristol-Myers Squibb Company (US)
  • Hoffmann-La Roche Ltd. (Switzerland)
  • Henry Schein Inc (US)
  • Pfizer Inc. (US)
Segmental Analysis:

On the basis of diagnosis, which includes physical exam, biopsy, blood tests, polymerase chain reaction, endoscopy, and others. Biopsy plays important role in diagnosis of this disorder, these tests include needle biopsy, CT-guided biopsy, ultrasound-guided biopsy, aspiration biopsy (fine-needle aspiration), skin biopsy, surgical biopsy, and others. Blood tests sub-segmented into Complete blood count (CB), Red Blood Cell Count (RBC), serum albumin test, total protein test, and others.

On the basis of treatments, the market is segmented into medications, supplements, and others. Medications is sub-segmented into Intravenous (IV) ceftriaxone (Rocephin), Intravenous (IV) penicillin, sulfamethoxazole-trimethoprim, SMX-TMP, oxycycline (Vibramycin), hydroxychloroquine (Plaquenil), and others. Supplements include vitamin supplements, mineral supplements, and others.

On the basis of end user, it is segmented into hospitals & clinics, academic institutes, medical research centers, and others.

Intended Audience
  • Whipple’s Disease Diagnostic and Treatment Supplies Companies
  • Whipple’s Disease Diagnostic and Treatment Supplies Providers
  • Medical Research Laboratories
  • Research and Development (R&D) Companies
  • Market Research and Consulting Service Providers
  • Potential Investors


About Market Research Future: we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact:

Market Research Future

Comments

Popular posts from this blog

Chatbots in Healthcare Market Research Report by Top Industry Vendors and Applications Scenario till 2023

Chatbots in Healthcare Market Overview Healthcare chatbots are programs which assist patients with queries. This reduces the burden on the clinical staff and lets them focus on their jobs. Automation of various workflow processes in the healthcare sector is likely to propel the demand for these virtual assistants. The global Chatbots in Healthcare Market is expected to touch USD 316.85 million by 2023 at 21.10% CAGR over the forecast period (2018-2023), as per Market Research Future (MRFR). It stood at USD 100.46 million in 2017. Rise of chronic diseases coupled with lack of medical experts to handle queries are main drivers of the market. For instance, cancer patients used chatbots to gain rapid assistance regarding medication and their adverse effects.  The  Chatbots in Healthcare Market   Free Growth Sample will provide valuable insight with an emphasis on the global market including some of the  major players  such As, ...

Idiopathic Pulmonary Fibrosis (IPF) Treatment Market Growth Drivers, Restraints and Opportunities, Forecast To 2025

Global Idiopathic Pulmonary Fibrosis (IPF) Treatment Market Size Research Report: Information by Treatment (Drug Class (Mitogen-Activated Protein Kinases (MAPK) Inhibitors, Tyrosine Kinase Inhibitors, Autotaxin Inhibitors, Others), Oxygen Therapy, Lung Transplant, Others) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2025 Global  Idiopathic Pulmonary Fibrosis (IPF) Treatment Market Size  Insights 2020 provides a unique tool for evaluating the Market, highlighting opportunities, and supporting strategic and tactical decision-making. This report recognizes that in this rapidly-evolving and competitive environment, up-to-date Marketing information is essential to monitor performance and make critical decisions for growth and profitability. Some of the key players operating for the global market analysis are  Boehringer Ingelheim GMBH, Biogen, Novartis AG, Medicinova, Inc., Bristol-Myers Squibb Company, Galapagos NV, F. Hoffmann-La R...

Kidney Dialysis Equipment Market Business Opportunities, Recent Updates and Developments 2019 To 2023

Kidney Dialysis Equipment Market  Development Opportunities and Global Industry Share Analysis by Top Leading Competitors – Latest MRFR Brief 2020 kidney dialysis equipment market is expected to witness tremendous growth owing to rising factors leading to kidney failure. Key factors such as growing acidosis, heart failure, change in sedentary lifestyle, uremic encephalopathy, vomiting, and loss of appetite leading to weight loss are contributing towards the growth of the market. According to the BCC Research report, the global market for kidney dialysis equipment is likely to grow at a CAGR of 5.7% from an assessed USD 16.5 billion in 2017, However, factors such as the high cost of dialysis procedures, expensive treatments, and rules and regulations associated with kidney dialysis equipment procedures are expected to restrict the market growth during the forecast period.. Some of the key players in the kidney dialysis equipment market are  Fresenius Medical Care AG ...